BRBoris K. Romanov

Boris K. Romanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Boris K. Romanov has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global Pharmacovigilance: Data for 2017–2025 with an Assessment of the Impact of the COVID-19 Pandemic

    by B. K. Romanov, E. Yu. Baidikova, D. A. Kozlov, U. M. Shirokova, E. D. Shchukin, Е. Ю. Байдикова

    INTRODUCTION. Continuous assessment of the dynamics of quantitative indicators and the impact of extraordinary events on them, such as the COVID-19 pandemic, is critically important for the development of the international drug safety monitoring program and national pharmacovigilance systems. AIM. This study aimed to provide a preliminary assessment of the dynamics of quantitative indicators in the World Health Organization (WHO) VigiBase database in the periods before, during and after the COVID-19 pandemic (2017–2025) to identify trends for the expected identification of trends potentially related to changes in the global pharmacovigilance system under extraordinary events. MATERIALS AND METHODS. The dynamics of the integral indicator of global pharmacovigilance, the annual total number of Individual Case Safety Reports (ICSR, cases) included in the VigiBase database in 2017–2025, divided into 3 periods of 3 years each: before the COVID-19 pandemic, during the pandemic and after the pandemic, was assessed. The data were analyzed using the VigiMatch statistical tool built into VigiLyze. RESULTS. The development of global pharmacovigilance system in the period before the COVID-19 pandemic was reflected in an annual increase of 300–400 thousand cases. In 2021, there was a sharp increase in the number of cases, and the proportion of reports for COVID-19 vaccines out of the total number of cases during the pandemic was 39.2%. In the post-COVID period, the number of cases in the global pharmacovigilance system was below the predicted values. Deviations of the actual number of cases included annually in the global pharmaco vigilance system from the expected in 2020–2025, as well as changes in the ranking of data, occurred mainly due to active safety monitoring of the COVID-19 vaccines. CONCLUSIONS. The identified trends in the global pharmacovigilance system in 2020–2025 may be preliminarily associated not only to the impact of the COVID-19 pandemic, but also to other causes and require further study.

  • Neural network modeling of the association of climate and non-contact injury with serum immunoglobulin A concentration in elite athletes: a retrospective cohort study

    by Natalia M. Buyanova, Anatoly G. Kochetov, Sergey P. Alpatov, Boris K. Romanov, Буянова Наталья Михайловна

    BACKGROUND: The role of serum immunoglobulin A is often underestimated; however, its functions in systemic protection and endotoxin clearance make it an important marker of the “cost of adaptation.” Serum immunoglobulin A concentration depends on sex and age, but the influence of contrast climate and the specifics of non-contact injury during the off-season has not been thoroughly studied before. AIM: To assess the influence of climatic factors and the specifics of non-contact injury on the variability of serum immunoglobulin A levels, taking into account age and sex, in elite athletes during the off-season. METHODS: A retrospective analysis of data from 7549 athletes (mean age 19.98 years) was performed. Comparative pairs were formed: “Biathlon–Triathlon” (climate influence with similar energy expenditure) and “Figure Skating–Speed Skating” (influence of biomechanics and injury patterns). Serum immunoglobulin A levels were measured using immunochemiluminescence analysis (g/L). Statistical analysis included estimation of 95% confidence intervals and neural network modeling (multilayer perceptron) to assess the contribution of factors. RESULTS: Reduced serum IgA levels were observed in athletes participating in winter and impact-loading sports. In biathletes, the level (1.67 g/L) was lower than in triathletes (1.73 g/L); the weight of the cold factor was –0.443. The minimum value was recorded in figure skating (1.40 g/L), which was significantly lower than that in speed skating (1.68 g/L). Modeling showed that impact loads (weight: –0.548) were associated with a lower level of serum immunoglobulin A. Sexual dimorphism (males females) and positive age-related trends were confirmed. CONCLUSION: Serum immunoglobulin A serves as a sensitive integrated marker of allostatic load. Cold stress and chronic trauma resulting from impact loads act as independent factors contributing to its reduction. The risk group includes female and young athletes specializing in complex coordination and winter sports.

  • Interaction of physical contact level and team modality in modulating serum immunoglobulin A concentration in elite athletes: a cross-sectional study

    by Natalia M. Buyanova, Anatoly G. Kochetov, Sergey P. Alpatov, Boris K. Romanov, Буянова Наталья Михайловна

    BACKGROUND: Serum immunoglobulin A (IgA) concentration is an important yet controversial marker of immune status in athletes. Data on its concentration the off-season and the influence of factors such as the level of physical contact and the individual/team nature of the sport are scarce. AIM: To evaluate the combined effect of the level of physical contact (contact vs low-contact) and sport modality (individual vs team) on serum IgA concentration in elite athletes during the off-season period. METHODS: A retrospective, cross-sectional study was conducted using anonymized data from 12,317 Russian national team athletes in boxing, tennis, basketball, and volleyball from 2012–2020. Groups were formed using a 2×2 factorial design: "contact" (boxing, basketball) vs "low-contact" (tennis, volleyball) and "individual" (boxing, tennis) vs "team" (basketball, volleyball) modality. RESULTS: Statistically significant differences were found in the median serum IgA concentrations, with all values remaining within the reference range. Athletes in contact sports (basketball: 1.81 g/L; boxing: 1.72 g/L) had significantly higher IgA levels than athletes in low-contact disciplines (volleyball: 1.57 g/L; tennis: 1.55 g/L). The factor analysis mathematically confirmed the existence of two independent constructs differentiated on the basis of physical contact. No significant effect of sport modality (individual/team) or factor interaction was observed. CONCLUSION: In the inter-competitive phase, the degree of physical contact acts as a key determinant modulating basal serum IgA within physiological limits, with elevated concentrations observed in contact sport athletes. The practical significance of these findings lies in the necessity of a sport-specific approach to immunological monitoring: the lower bound of the reference range considered normal for low-contact disciplines may be inadequate for athletes practicing contact-intensive sports.

  • Side effects of SGLT-2 inhibitors

    by E.N. Saykina, M.L. Maksimov, B.K. Romanov

    This review presents updated information on the side effects of sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors), the most modern group of hypoglycemic agents. In addition to their hypoglycemic action, SGLT-2 inhibitors exhibit secondary pharmacodynamics (side effects), providing cardioprotective, antiarrhythmic, anti-apoptotic, anti-inflammatory, nephroprotective, and neuroprotective effects, while reducing total body fat and visceral fat. The use of these side effects is desirable and promising for the treatment of patients with diabetes, especially in the presence of comorbidities. However, the use of SGLT-2 inhibitors may lead to undesirable reactions, the most common of which are dehydration (hypovolemia), glycosuria, and fungal infections of the genitalia and urinary tract. The most frequent serious outcomes of adverse reactions include euglycemic diabetic ketoacidosis, lower limb amputation, and acute kidney injury. Recommendations for the prevention of adverse reactions are presented.

  • Adverse reactions to SGLT-2 inhibitors in children with diabetes mellitus

    by E. N. Saykina, B. K. Romanov, M. L. Maksimov

    The purpose of the study: to conduct an expert assessment of post-registration data from real clinical practice on the safety of SGLT-2 inhibitors in children. Objectives of the study: to establish quantitative and qualitative characteristics of adverse reactions (ARs) when using SGLT2 inhibitors in children. Conclusion: The results of the analysis of real clinical practice data on the safety of SGLT-2 inhibitors in children suggest a large volume of consumption of these drugs, which can be indirectly indicated by the number of cases presented. Differences from adults in the structure of use and in the manifestations of side effects were established. Practical recommendations: It is necessary to take into account the established risks when using SGLT-2 inhibitors in children, since they can cause serious adverse reactions and require attention from pediatricians and parents, until regulatory authorities have approved the corresponding changes to the instructions for medical use of these drugs.

  • Open Access

    Review of alternative antimicrobial therapies

    by Svetlana V. Romanova, Anastasia V. Tsypkina, Tatiana I. Subbotina, Sergey M. Yudin, Anton A. Keskinov, Valentin V. Makarov, Angelica V. Zagainova, Boris K. Romanov, Цыпкина Анастасия Валерьевна, Юдин Сергей Михайлович, et al.

    Antimicrobial resistance is a most challenging global public health problem. Today, the number of antibiotic-resistant bacterial strains has been increasing to the point of economic and social disaster. Thus, it is necessary to find alternative effective approaches to antimicrobial therapy and prevention. The most promising alternative antimicrobial therapies include antibodies; bacteriophages and bacteriophage-derived enzymes; antivirulence agents; probiotics and microbiome-modulating agents; immunostimulants; host-protective antimicrobial peptides; nanoparticles and liposomes, etc. A comprehensive approach to treating infections without exacerbating the antimicrobial resistance problem provides for combining these alternative treatments with strategies to maintain the efficacy of existing antimicrobial agents. The review is aimed to summarize data on the causes and mechanisms underlying the development of resistance; limitations of standard treatments; alternative resistance-inhibiting treatments, their advantages and disadvantages; and future challenges. The paper presents summary of alternative antimicrobial agents at different stages of pharmaceutical development.


  • Open Access

    Computerized systems and databases for pharmacovigilance in Russia

    by B. K. Romanov, E. N. Saykina, E. Yu. Baidikova, U. M. Shirokova, E. D. Shchukin, Е. Ю. Байдикова

    The results of identifying new risks for pharmacovigilance systems and databases in Russia, including the Roszdravnadzor's web-based pharmacovigilance system, are presented. The lack of information in the database on pharmacovigilance of the Eur asian Economic Union and problems with updating programs and using alternative systems were noted. Changes in RWD/RWE information in global pharmacovigilance over the past 5 years.Objectives. Identification of new risks associated with pharmacovigilance systems and databases in Russia. Materials and methods. The materials were obtained by interviewing 138 pharmacovigilance specialists and from regula tory legal acts, publications, computerized systems, and databases through open and authorized access. Sociological methods were used: survey in Telegram-group «Pharmacovigilance CIS» in October 2024 and information-analytical methods: user testing, review, and analysis of Russian and foreign systems and programs, including databases for pharmacovigilance, regu latory documentation, and bibliography.Results. 17 % of pharmacovigilance specialists use exclusively Russian software in their computerized systems and data bases, 29 % use only foreign software, 35 % use both Russian and foreign software, and 19 % find it difficult to classify their systems and programs as domestic or foreign. The results of user testing indicate that there are problems and risks with access ing Roszdravnadzor’s web-based pharmacovigilance system via foreign browsers in current versions of Windows, Android, MacOS, iOS, and Unix operating systems. The unified pharmacovigilance database of the Eurasian Economic Union as of No vember 5, 2024, contains no public access notifications. The composition of data in the global database, VigiBase, has changed over 5 years: the largest number of cases now relates to COVID-19 vaccines. Russian data were not included in EudraVigilance and VigiBase (from October 10, 2020), which does not allow them to be considered in the global analysis.Conclusion. New potential risks for computerized systems and databases for pharmacovigilance in Russia have been iden tified — loss of data and reduction in the quality of analysis.


  • SYSTEMATIC ANALYSIS OF THE CAUSES AND FACTORS OF ADVERSE REACTIONS OF OMALIZUMAB

    by Schneider K.O., Maksimov M.L., Romanov B.K.

    The article presents a systematic analysis of the causes and factors of adverse reactions to the use of omalizumab. Methods of monitoring appeals, expert assessment, and interviewing medical specialists were applied. The analysis showed that in Russia there is a "declarative passivity" of medical workers and patients in relation to reports of adverse reactions to the use of omalizumab, which is associated with a high workload and reluctance on the part of medical workers to issue a notification, lack of knowledge about the procedure for notification, fear of being punished for possible incorrect actions on the use of the drug; on the part of patients – by not knowing their rights and the procedure for submitting a report, by fear of spoiling relations with the attending physician. Such passivity and closeness hinders the formation of a system for the prevention of drug safety violations. The data obtained in the course of the study (on the frequency and structure of adverse reactions to the use of omalizumab in clinical practice in children and adults; information on the most dangerous combinations of omalizumab with other drugs; The characteristics of the causes and factors of adverse reactions to the use of omalizumab, as well as the untimely submission of notifications about them, have become the theoretical basis for the development of recommendations for improving pharmacovigilance activities to ensure the safety of the use of omalisamab in children and adults, which includes 4 areas: creation of organizational conditions to ensure the safety of the use of omalisamab in children and adults in medical organizations; prevention of adverse reactions to the use of omalizumab at the preclinical stage; optimization of clinical choice and support for decision-making by a medical specialist (doctor) when prescribing omalizumab based on a risk-based approach, taking into account the individual characteristics of the patient and the clinical situation; improving the quality of safety monitoring of the use of omalizumab.


  • GLOBAL SAFETY OF BENRALIZUMAB: PHARMACOVIGILANCE ANALYSIS OF SPONTANEOUS REPORT DATA

    by Shnaider K.O., Maksimov M.L., Kondrachin A.P., Romanov B.K., Martynova S.A.

    Ensuring drug safety is one of the key areas of modern medicine and pharmacy. Recent studies and publications confirm the long-term effectiveness and safety of using benralizumab. However, when making clinical decisions, it is important to consider the risks associated with biological therapy in order to provide adequate consultations for patients and effectively monitor potential adverse reactions. This article examines serious and significant adverse reactions associated with the use of benralizumab, as well as an analysis of the World Health Organization's global database, VigiBase, regarding adverse reactions to benralizumab. The data obtained on adverse reactions serve as a theoretical basis for improving the pharmacovigilance and drug monitoring system in Russia, presenting significant practical value for physicians, researchers, and healthcare professionals.

  • Open Access

    Comparison of the efficacy of paracetamol and ibuprofen for fever in children under 5 years of age

    by Vadim V. Abramov, Maxim L. Maximov, Boris K. Romanov, Anastasia A. Shikaleva, Maksim L. Maksimov, Максимов Максим Леонидович

    Fever accounts for a significant proportion of pediatric emergency consultations, with up to 40% of children under the age of five see a doctor for this condition. Fever is usually the result of acute respiratory viral infection, is short-lived and resolves on its own. However, in the hyperergic variant or with depletion of compensatory mechanisms, fever can be the cause of the development of pathological conditions. Therefore, timely and effective control of fever has always been a subject of interest to parents and pediatricians. Current guidelines define fever above 38.5 °C as a condition in which the use of antipyretics is indicated. Paracetamol (acetaminophen) and ibuprofen are the most widely prescribed and available over-the-counter antipyretics in children. Despite the widespread use of these drugs, recommendations for the treatment of young children remain varied, leading to irrational use of antipyretics. Therefore, the aim of this review is to analyze existing clinical trials comparing paracetamol and ibuprofen to develop guidelines for pediatricians on the management of febrile pediatric patients.